

1449B/PTO Rev. 10/95		U.S. Department of Commerce Patent and Trademark Office		Complete If Known	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/553,291
				Filing Date	October 14, 2005
				First Named Inventor	Mary J. EATON
				Group Art Unit	1647
				Examiner Name	
Sheet	1	of		Attorney Docket Number	US 1442/05 (VA)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book), magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, country, where published, source.	T <sup>2</sup>
		Berg-Johnsen J, Roste G, Solgaard T, Lundar T. Continuous intrathecal infusion of baclofen. A new therapeutic method for spasticity. Tidsskr Nor Laegeforen 1998;118: 3256-3260.	
		Kuraishi Y, Hirota N, Satoh M, Takagi H. Antinociceptive effects of intrathecal opioids, noradrenaline and serotonin in rats: mechanical and thermal algescic tests. Brain Res 1985;326: 168-171.	
		Fakhoury T, Abou-Khalil B, Blumenkopf B. EEG changes in intrathecal baclofen overdose: a case report and review of the literature. Electroencephalogr Clin Neurophysiol 1998;107: 339-342.	
		Postma TJ, Oenema D, Terpstra S, Bouma J. Cost analysis of the treatment of severe spinal spasticity with a continuous intrathecal baclofen infusion system. Pharmacoeconomics 1999;15: 395-404.	
		Zed PJ, Stiver HG, Devonshire V, Jewesson PJ. Continuous intrathecal pump infusion of baclofen with antibiotic drugs for treatment of pump-associated meningitis. Case report. J Neurosurg 2000;92: 347-349.	
		Gock SB, Wong SH, Stormo KA, Jentzen JM. Self-intoxication with morphine obtained from an infusion pump. J Anal Toxicol 1999;23: 130-133.	
		Sauter K, Kaufman H, Bloomfield S, Cline S. Treatment of high-dose intrathecal morphine overdose. case report. J Neurosurg 1994;81: 143-146.	
		Wu CL and Patt RB. Accidental overdose of systemic morphine during intended refill on intrathecal infusion device. Anesth Analges 1992;75: 130-132.	
		Winnie AP, Pappas GD, DasGupta TK, Wang H. Subarachnoid adrenal medullary transplants for terminal cancer pain. Anesthesiology 1993;79: 644-653.	
		Wu HH, Wilcox GL, McLoon SC. Implantation of AtT-20 or genetically modified AtT-20/hENK cells in mouse spinal cord induced antinociception and opioid tolerance. J Neurosci 1994;14: 4806-4814.	

Examiner Signature	/Daniel Gamett/ (12/14/2007)	Date Considered	
--------------------	------------------------------	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DG/

1449B/PTO  
Rev. 10/95U.S. Department of Commerce  
Patent and Trademark Office**LIST OF PRIOR ART CITED BY  
APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/553,291
Filing Date	October 14, 2005
First Named Inventor	Mary J. EATON
Group Art Unit	1647
Examiner Name	
Attorney Docket Number	US 1442/05 (VA)

Sheet

2

of

6

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book), magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, country, where published, source.	T <sup>2</sup>
		Eaton MJ, Dancousse HR, Santiago DI, Whittemore SR. Lumbar transplants of immortalized serotonergic neurons alleviates chronic neuropathic pain. Pain 1997;72: 59-69.	
		Eaton MJ, Plunkett JA, Martinez MA, Lopez T. Transplants of neuronal cells bio-engineered to synthesize GABA alleviate chronic neuropathic pain. Cell Transplant 1999;8: 87-101.	
		Cejas PJ, Martinez M, Karmally S, McKillop M. Lumbar transplant of neurons genetically modified to secrete brain-derived neurotrophic factor attenuate allodynia and hyperalgesia after sciatic nerve constriction. Pain 2000;86: 195-210.	
		Eaton MJ and Whittemore SR. Autocrine BDNF secretion enhances the survival and serotonergic differentiation of raphe neuronal precursor cells grafted into the adult rat CNS. Exp Neurol 1996;140: 105-114.	
		Andrews PW, Damjanov I, Simon D, Banting GS. Pluripotent embryonal carcinoma clones derived from human teratocarcinoma cell line Tera-2. Lab Invest 1984;50: 147-162.	
		Pleasure SJ, Page C, Lee VMY. Pure, postmitotic, polarized human neurons derived from NTera 2 cells provide a system for expressing exogenous proteins in terminally differentiated neurons. J Neurosci 1992;12: 1802-1815.	
		Borlongan CV, Tajima Y, Trojanowski JQ, Lee VMY. Transplantation of cryopreserved human embryonal carcinoma-derived (NT2N cells) promotes functional recovery in ischemic rats. Exp Neurol 1998;149: 310-321.	
		Trojanowski JQ, Kleppner SR, Hartley RS, Miyazono M. Transfectable and transplantable postmitotic human neurons: potential "platform" for gene therapy of nervous system diseases. Exp Neurol 1997;144: 92-97.	
		Kondziolka D, Wechsler L, Goldstein S, Meltzer C. Transplantation of cultured human neuronal cells for patients with stroke. Neurology 2000;55: 565-569.	
		Nelson PT, Kondziolka D, Wechsler L, Goldstein S. Clonal human (hNT) neuron grafts for stroke therapy: neuropathology in a patient 27 months after implantation. Am J Pathol 2002;160: 1201-1206.	

Examiner  
Signature

/Daniel Gamett/ (12/14/2007)

Date  
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DG/

1449B/PTO  
Rev. 10/95U.S. Department of Commerce  
Patent and Trademark Office**LIST OF PRIOR ART CITED BY  
APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/553,291
Filing Date	October 14, 2005
First Named Inventor	Mary J. EATON
Group Art Unit	1647
Examiner Name	
Attorney Docket Number	US 1442/05 (VA)

Sheet

3

of

6

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book), magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, country, where published, source.	T <sup>2</sup>
		Eaton MJ, Frydel B, Lopez T, Nie X. Generation and initial characterization of conditionally immortalized chromaffin cells. J Cell Biochem 1999;79: 38-57.	
		Cheung WMW, Fu WY, Hui WS, Ip NY. Production of human CNS neurons from embryonal carcinoma cells using a cell aggregation method. BioTechniques 1999;26: 946-954.	
		Samat HB, Noehlin D, Born DE. Neuronal nuclear antigen (NeuN): a marker of neuronal maturation in early human fetal nervous system. Brain Dev 1998;20: 88-94.	
		Daadi MM, Saporta S, Willing AE, Zigova T. In vitro induction and in vivo expression of bcl-2 in the hNT neurons. Brain Res Bull 2001;56: 147-152.	
		Eaton MJ, Staley JK, Globus MYT, Whittemore SR. Developmental regulation of early serotonergic neuronal differentiation: the role of brain-derived neurotrophic factor and membrane depolarization. Dev Biol 1995;170: 169-182.	
		Bennett DJ, Gorassini M, Fouad K, Sanelli L. Spasticity in rats with sacral spinal cord injury. J Neurotrauma 1999;16: 69-84.	
		Siddall PJ, Yezierski RP, Loeser J. Pain following spinal cord injury: clinical features, prevalence, and taxonomy. IASP Newsletter 2000;3: 3-7 (13 pages).	
		Hargreaves K, Dubner R, Brown F, Flores C. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988;32: 77-88.	
		Yezierski RP, Liu S, Ruenes GL, Kajander KJ. Excitotoxic spinal cord injury: behavioral and morphological characteristics of a central pain model. Pain 1998;75: 141-155.	
		Abraham KE, McGinty JF, Brewer KL. The role of kainic acid/AMPA and metabotropic glutamate receptors in the regulation of opioid mRNA expression and the onset of pain-related behavior following excitotoxic spinal cord injury. Neurosci 2001;104: 863-874.	

Examiner  
Signature

/Daniel Gamett/ (12/14/2007)

Date

Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DG/

1449B/PTO  
Rev. 10/95U.S. Department of Commerce  
Patent and Trademark Office**LIST OF PRIOR ART CITED BY  
APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/553,291
Filing Date	October 14, 2005
First Named Inventor	Mary J. EATON
Group Art Unit	1647
Examiner Name	
Attorney Docket Number	US 1442/05 (VA)

Sheet

4

of

6

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book), magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, country, where published, source.	T <sup>2</sup>
		Abraham KE and Brewer KL. Expression of c-fos mRNA is increased and related to dynorphin mRNA expression following excitotoxic spinal cord injury in the rat. <i>Neurosci Lett</i> 2001;307: 187-191.	
		Plunkett JA, Yu CG, Easton JM, Bethea JR. Effects of interleukin-10 (IL-10) on pain behavior and gene expression following excitotoxic spinal cord injury in the rat. <i>Exp Neurol</i> 2001;168: 144-154.	
		Abraham KE, McGinty JF, Brewer KL. Spinal and supraspinal changes in opioid mRNA expression are related to the onset of pain behaviors following spinal cord injury. <i>Pain</i> 2001;90: 181-190.	
		Abraham KE, Brewer KL, McGinty JF. Opioid peptide messenger RNA expression is increased at spinal and supraspinal levels following excitotoxic spinal cord injury. <i>Neurosci</i> 2000;99: 189-197.	
		Morrow TJ, Paulson PE, Brewer KL, Yezierski RP. Chronic, selective forebrain responses to excitotoxic dorsal horn injury. <i>Exp Neurol</i> 2000;161: 220-226.	
		Brewer KL and Yezierski RP. Effects of adrenal medullary transplants on pain-related behaviors following excitotoxic spinal cord injury. <i>Pain</i> 1998;798: 83-92.	
		Schwartz ED, Yezierski RP, Pattany PM, Quencer RM. Diffusion-weighted MR imaging in a rat model of syringomyelia after excitotoxic spinal cord injury. <i>Am J Neuroradiol</i> 1999;20: 1422-1428.	
		Yezierski RP, Santana M, Park SH, Madsen PW. Neuronal degeneration and spinal cavitation following intraspinal injections of quisqualic acid in the rat. <i>J Neurotrauma</i> 1993;10: 445-456.	
		Widerstrom-Noga EG, Felipe-Cuervo E, Broton JG, Duncan RC. Perceived difficulty in dealing with consequences of spinal cord injury. <i>Arch Phys Med Rehabil</i> 1999;80: 580-586.	
		Yezierski RP. Pain following spinal cord injury: the clinical problem and experimental studies. <i>Pain</i> 1996;68: 185-194.	

Examiner  
Signature

/Daniel Gamett/ (12/14/2007)

Date  
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DG/

1449B/PTO  
Rev. 10/95U.S. Department of Commerce  
Patent and Trademark Office**LIST OF PRIOR ART CITED BY  
APPLICANT**

(use as many sheets as necessary)

Sheet

5

of

6

**Complete if Known**

Application Number	10/553,291
Filing Date	October 14, 2005
First Named Inventor	Mary J. EATON
Group Art Unit	1647
Examiner Name	
Attorney Docket Number	US 1442/05 (VA)

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book), magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, country, where published, source.	T <sup>2</sup>
		Bennett GJ and Xie Y-K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988;33: 87-107.	
		Kim SH and Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992;50: 355-363.	
		Yezierski RP, Liu S, Ruenes GL, Kajander KJ. Behavioral and pathological characteristics of a central pain model following spinal injury. VIIIth World Congress on Pain 1996;	
		Yezierski RP and Park SH. The mechanosensitivity of spinal sensory neurons following intraspinal injections of quisqualic acid in the rat. Neurosci Lett 1998;157: 115-119.	
		Smart D, Hirst RA, Hirota K, Grandy DK, Lambert DG. The effects of recombinant rat mu-opioid receptor activation in CHO cells on phospholipase C, [Ca <sup>2+</sup> ] <sub>i</sub> and adenylyl cyclase. Br J Pharmacol 1997; 120: 1165-1171.	
		Schumm MA, Castellanos DA, Frydel BL, Sagen J. Direct cell-cell contact required for neurotrophic effect of chromaffin cells on neural progenitor cells. Brain Res., 146 (1-2):1-13.(2003).	
		Schumm MA, Castellanos DA, Frydel BR, Sagen J. Enhanced viability and neuronal differentiation of neural progenitors by chromaffin cell co-culture. Brain Res., 137(2):115-25(2002).	
		Schumm MA, Castellanos DA, Frydel BR, Sagen J. Improved neural progenitor cell survival when grafted with chromaffin cells in the rat striatum. Exp Neurol., 185(1):133-42 (2004).	
		Hama AT, Siegan JB, Herzberg U, Sagen J. 1. NMDA-induced spinal hypersensitivity is reduced by naturally derived peptide analog [Ser1]histogranin. Pharmacol Biochem Behav. 62(1):67-74 (1999).	
		Siegan JB, Hama AT, Sagen J. Suppression of neuropathic pain by a naturally-derived peptide with NMDA antagonist activity. Brain Res., 755(2):331-4 (1997).	

Examiner  
Signature

/Daniel Gamett/ (12/14/2007)

Date  
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DG/

1449B/PTO  
Rev. 10/95U.S. Department of Commerce  
Patent and Trademark Office**LIST OF PRIOR ART CITED BY  
APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/553,291
Filing Date	October 14, 2005
First Named Inventor	Mary J. EATON
Group Art Unit	1647
Examiner Name	
Attorney Docket Number	US 1442/05 (VA)

Sheet

6

of

6

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book), magazine, journal, serial, symposium, catalog, etc., date, page(s), volume-issue number(s), Publisher, country, where published, source.	T <sup>2</sup>
		Siegan JB, Sagen J. A natural peptide with NMDA inhibitory activity reduces tonic pain in the formalin model. Neuroreport., 8(6):1379-81 (1997).	
		Eaton MJ, Herman JP, Jullien N, Lopez TL, Martinez M, Huang J. Immortalized chromaffin cells disimmortalized with Cre/lox site-directed recombination for use in cell therapy for pain after partial nerve injury. Exp Neurol. 175(1):49-60 (2002).	
		Eaton MJ, Martinez M, Karmally S, Lopez T, Sagen J. Initial characterization of the transplant of immortalized chromaffin cells for the attenuation of chronic neuropathic pain. Cell Transplant., 9(5):637-56 (2000).	
		NasiriNezhad F, Sagen J. NMDA antagonist peptide supplementation enhances pain alleviation by adrenal medullary transplants. Cell Transplant., 14(4):203-11 (2005).	
		Hama A, Sagen J. Selective antihyperalgesic effect of [Ser <sup>1</sup> ] histogram on complete Freund's adjuvant-induced hyperalgesia in rats. PAIN 95:15-21 (2002).	

Examiner  
Signature

/Daniel Gamett/ (12/14/2007)

Date  
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DG/